YH-003 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YH-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-003 overview
YH-003 is under development for the treatment of solid tumors including metastatic melanoma, ocular melanoma, metastatic pancreatic ductal adenocarcinoma (PDAC). The drug candidate is a monoclonal antibody that acts by targeting CD40. It is developed based on hybridoma technology. It is administered through parenteral and intravenous route.
Eucure (Beijing) Biopharma overview
Eucure (Beijing) Biopharma is a biotechnology company that discovery and development of innovative immuno-oncology targeted antibodies. The company is headquartered China.
For a complete picture of YH-003’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
